CN102258529A - Compound ivermectin injection and preparation method thereof - Google Patents

Compound ivermectin injection and preparation method thereof Download PDF

Info

Publication number
CN102258529A
CN102258529A CN2011101119207A CN201110111920A CN102258529A CN 102258529 A CN102258529 A CN 102258529A CN 2011101119207 A CN2011101119207 A CN 2011101119207A CN 201110111920 A CN201110111920 A CN 201110111920A CN 102258529 A CN102258529 A CN 102258529A
Authority
CN
China
Prior art keywords
injection
ivermectin
parasitic
compound
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2011101119207A
Other languages
Chinese (zh)
Other versions
CN102258529B (en
Inventor
操继跃
张卫元
陈翠兰
张永丹
李�荣
张翠平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changsha SPN Animal Pharmaceutical Co., Ltd.
Original Assignee
WUHAN HVSEN BIOTECHNOLOGY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WUHAN HVSEN BIOTECHNOLOGY CO Ltd filed Critical WUHAN HVSEN BIOTECHNOLOGY CO Ltd
Priority to CN2011101119207A priority Critical patent/CN102258529B/en
Publication of CN102258529A publication Critical patent/CN102258529A/en
Application granted granted Critical
Publication of CN102258529B publication Critical patent/CN102258529B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention belongs to the technical field of veterinary anti-parasitic medicaments, particularly relates to a compound ivermectin injection and a preparation method thereof, and aims to provide an injection for treating parasitic infection of livestock, expanding an anti-parasitic spectrum and enhancing a therapeutic effect and a preparation method thereof. Every 100ml of compound ivermectin injection comprises 0.5-2g of ivermectin, 2.5-10g of albendazole sulfoxide, 5-15ml of polyethylene glycol 400 (PEG400), 1-10ml of acetic ether, 0.5-2ml of benzyl alcohol, 0.05-0.2ml of alpha-thioglycerol, 10-30ml of dimethyl sulfoxide and the balance of propylene glycol. In the injection, the ivermectin and the albendazole sulfoxide are used as anti-parasitic main components; the injection has double complementary advantages; the anti-parasitic spectrum is expanded; the drug resistance probability of parasites can be effectively reduced; and the sensitivity of the parasites is improved. The invention brings a completely new situation for safely, effectively and conveniently preventing and treating parasitic diseases in animal husbandry and aquaculture of China.

Description

A kind of compound ivermectin injection and preparation method thereof
Technical field
The present invention relates to anti-parasite medicine for animal use thing technical field, be specifically related to a kind of compound ivermectin injection and preparation method thereof.
Background technology
Ivermectin is a kind of novel Macrolide antiparasitic, with its wide spectrum, efficient (nematicide, insecticide and demodicid mite are all had efficiently killing effect), toxic and side effects is little, consumption is little, safe, the residence time characteristics such as lacks and is widely used in the herding production in animal food.
Ivermectin has only ordinary preparation at present, and each administration weak point of holding time needs multiple dosing, exists and uses inconvenience, expends shortcomings such as a large amount of manpower and materials again, presses for the new product of research, to adapt to Developing of Animal Industry.Ivermectin has the stronger effect of killing to animal body entozoa (nematicide) and vermin (Ticks, demodicid mite, louse, flea etc.); Albendazole-sulfoxide is all killed effect to nematicide, cestode, trematodiasis.In view of two kinds of medicines all have stronger anti-insect activity and have complementary action on pest-resistant spectrum, successfully developing its compound injection has its significance, has had not yet to see the correlational study report.
Summary of the invention
At the deficiencies in the prior art, the object of the present invention is to provide that a kind of preparation method is simple, cost of material is low, efficient, wide spectrum and animal compound ivermectin injection of being difficult for developing immunity to drugs and preparation method thereof.
The present invention is compound in ivermectin and albendazole-sulfoxide in the solvent in the proper ratio, and combines dexterously by compositions such as suitable stabilizing agent and antibacterial, makes stable compound preparation.On pest-resistant spectrum, have the complementary effect of double dominant thereby reach, enlarge pest-resistant spectrum, improve pest-resistant curative effect, reduce the drug resistance of polypide, improve parasitic sensitivity.
The objective of the invention is to be achieved through the following technical solutions:
A kind of compound ivermectin injection, this injection of every 100ml comprises: the propylene glycol of ivermectin 0.5~2g, albendazole-sulfoxide 2.5~10g, PEG400 (PEG400) 5~15ml, ethyl acetate 1~10ml, benzyl alcohol 0.5~2ml, α-thioglycerol 0.05~0.2ml, dimethyl sulfoxide 10~30ml and surplus.
The preparation method step of above-mentioned compound ivermectin injection is as follows:
(1) takes by weighing ivermectin and join in the ethyl acetate, stir to clarify, get solution A;
(2) take by weighing albendazole-sulfoxide and join in the dimethyl sulfoxide, stop heating immediately after heating makes it to dissolve fully, be cooled to 40 ℃, stir to clarify, get solution B;
(3) merge solution A and solution B, add PEG400, α-thioglycerol and benzyl alcohol after stirring successively, stir, treat that solution clarification back adds propylene glycol, promptly gets compound ivermectin injection.
Advantage of the present invention and beneficial effect are:
Selected ivermectin and albendazole-sulfoxide to be prepared into compound preparation among the present invention dexterously, formed dual pest-resistant advantage, had the wide spectrum pest-resistant effect, improved parasitic sensitivity according to certain ratio.In addition in this preparation because the adding of PEG400 has improved the chelating degree between medicine and solvent and the cosolvent, consequently improved the stability of this compound preparation greatly.Experiment showed, that ivermectin and albendazole-sulfoxide unite use curative effect is strengthened, clinical practice is extensive, can be widely used in the treatment of animal parasite disease, reduces parasitic infection rate, improves the economic benefit that animal husbandry is cultured.
The specific embodiment
Below in conjunction with specific embodiment the inventive method is described in further detail.
Embodiment 1~5:
Embodiment 1~5 has all prepared a kind of compound ivermectin injection of the present invention, and the composition of raw materials of every 100ml injection of each embodiment is seen following table 1.
Table 1
Component Embodiment 1 Embodiment 2 Embodiment 3 Embodiment 4 Embodiment 5
Ivermectin (g) 0.5 0.5 1 1.5 2
Albendazole-sulfoxide (g) 2.5 2.5 5 7.5 10
Ethyl acetate (ml) 1 2 5 10 10
PEG400(ml) 5 7.5 10 12 15
Dimethyl sulfoxide (ml) 10 15 20 25 30
α-thioglycerol (ml) 0.05 0.1 0.1 0.1 0.2
Benzyl alcohol (ml) 1 1.5 2 0.5 1.5
Propylene glycol Surplus Surplus Surplus Surplus Surplus
It is as follows that the raw material of above-mentioned prescription makes the method step of compound ivermectin injection of the present invention:
(1) takes by weighing ivermectin and join in the ethyl acetate, stir to clarify, get solution A;
(2) take by weighing albendazole-sulfoxide and join in the dimethyl sulfoxide, stop heating immediately after heating makes it to dissolve fully, be cooled to 40 ℃, stir to clarify, get solution B;
(3) merge solution A and solution B, add PEG400, α-thioglycerol and benzyl alcohol after stirring successively, stir, treat that solution clarification back adds propylene glycol, promptly get compound ivermectin injection, testing result sees Table 2.
Each embodiment result of table 2
The result of table 2 proves that the compound ivermectin injection of the foregoing description 1~5 preparation is faint yellow supernatant liquid, (temperature is 40 ± 2 ℃ to accelerated test, relative humidity is 65 ± 5%) under the condition, the content of principal agent ivermectin, albendazole-sulfoxide is more than 98% (m/m) of labelled amount after three months, meets the requirements.
From the result, can find, the product that adds the PEG400 preparation in the test method does not add prepared test specimen and compares, has better stability (controlled trial: except not adding the PEG400, all the other components and preparation method are all with embodiment 2, the test specimen that makes after having passed through three months accelerated tests under the similarity condition, the equal not enough labelled amount of content of ivermectin and albendazole-sulfoxide 95%).PEG400 belongs to macromolecular substances, has peptizaiton and chelation preferably, can organically combine with small-molecule drug.Therefore the adding of PEG400 has improved the stability of compound ivermectin injection greatly in this compound preparation, and the content and the character of accelerated test principal agent after three months all do not have obvious variation.
The clinical trial part
1 material and method
1.1 material
1.1.1 compound ivermectin injection (containing ivermectin 0.5g, albendazole-sulfoxide 2.5g in per 100 milliliters): lot number 110125, Wuhan Hvsen Biotechnology Co., Ltd. provides, and is got by embodiment 2 preparations.
1.1.2 ivermectin injection: specification is that every 50mL contains ivermectin 0.5g, lot number 110301, and Sichuan Province elite animal pharmaceutcal corporation, Ltd produces.
1.1.3 levamisole hydrochloride injection treatment of control group group: specification is 10mL, contains levamisole 0.5g, lot number 110310, and Hebei Yuanzheng Medicine Co., Ltd produces.
1.1.4 experimental animal: the two-way cross pig of 300 4 months ages in days that the Huangshi pig farm is raised, carry out the stool examination of pig parasitic ovum, and do itemized record, select to infect 42 more serious pigs and be divided into 7 groups at random, 6 every group, carry out labelling, test.
1.2 method
1.2.1 test pig parasitic infection condition survey: before the test 6 test pig of the 7th group are butchered, carry out the inspection of distoma hepaticum, cestode, gastrointestinal nematode and other parasitic infection amounts.Determine the average infection intensity of this area pig main parasitic worm.
1.2.2 respectively organize the processing of experimental animal: press every 50kg body weight subcutaneous injection 0.5,1,1.5mL with compound ivermectin injection respectively for the 1st, 2,3 groups; The 4th group with ivermectin injection by every 50kg body weight subcutaneous injection 1mL; Use the levamisole hydrochloride injection for the 5th group, by every kg body weight intramuscular injection 0.5mL; The 6th group is matched group.In administration 7,14, respectively organize the faecal egg inspection of test pig after 21d days with the McMaster method, to observe and infect worm's ovum minimizing situation, the worm's ovum slip calculates by following formula.
Figure BDA0000058450440000041
1.2.3 the average infection intensity of each experimental animal changes before and after the test: the Total Test pig send the slaughterhouse to butcher after the off-test, and collects the inspection that internal organs are done distoma hepaticum, cestode, gastrointestinal nematode and other parasitic infection amounts.Determine the test front and back and respectively organize the situation of change of average infection intensity, deworming rates is calculated by following formula.
Figure BDA0000058450440000042
2 result of the tests
Result of the test sees Table 1, table 2, table 3, table 4, table 5.
Table 1 test pig farm pig parasitic infection intensity statistics
Parasite species Infection rate (%) Infective dose (bar/only) Average infection intensity (bar/only)
Distoma hepaticum 50 10~25 20
Cestode 60 5~30 26
The Strongyloides ransomi disease 100 20~200 112
The stomach strongylasis 100 30~60 40
Whipworm 20 50~150 85
The total infectiosity of mean parasitized worm 283
Table 2 faecal egg infective dose digestive tract worm's ovum number reduces test
Figure BDA0000058450440000051
Average infection intensity situation of change before and after the test of table 3 distoma hepaticum
Group Before the test (bar/only) The test back (bar/only) Kill rate (%)
1 20 12 44.4
2 20 5 81.5
3 20 1 92.6
4 20 22 0
5 20 21 0
6 20 28 0
Average infection intensity situation of change before and after the test of table 4 cestode
Group Before the test (bar/only) The test back (bar/only) Kill rate (%)
1 26 9 65.4
2 26 2 92.3
3 26 0 100
4 26 27 0
5 26 27 0
6 26 30 0
Average infection intensity situation of change before and after the test of table 5 gastrointestinal tract nematicide
Group Before the test (bar/only) The test back (bar/only) Kill rate (%)
1 79 15 81.1
2 79 5 93.7
3 79 2 97.5
4 79 17 78.5
5 79 12 84.8
6 79 98 0
The overall anthelminthic effect of table 6
Group Before the test (bar/only) The test back (bar/only) Kill rate (%)
1 283 94 66.8
2 283 23 90.9
3 283 12 95.8
4 283 119 58.0
5 283 103 63.6
6 283 298 0
3 discuss
3.1, prove that compound ivermectin injection of the present invention has the extraordinary effectiveness of killing to pork liver plate trematodiasis, cestode, gastrointestinal tract nematicide by clinical trial.Test data shows that by every 50kg body weight subcutaneous injection 1mL, the worm's ovum negative conversion rate reaches 100% behind the 14d, and deworming rates reaches 93.7%.This test proves that fully the compound ivermectin injection prescription is scientific and reasonable, can enlarge the pest-resistant spectrum and the anthelmintic efficiency of compound preparation.
3.2 people use its derivant of avilamycin to produce serious Drug resistance in a large number disorderly over many years.This test has also proved this point, and the problem that clinical application effect reduces, drug residue increases is appeared suddenly day by day.Compound Synergistic, expansion anthelmintic spectrum, the polyenergic purpose of a medicine of reaching by two medicines can address the above problem preferably.
3.3 according to the data introduction, ivermectin is to distoma hepaticum and cestode poor effect, but compound ivermectin group deworming rates shows that all it has powerful anthelminthic effect (92.6% and 100%) to pork liver plate trematodiasis and cestode in this test, with point out that albendazole-sulfoxide is consistent to the result that cestode, trematodiasis have very strong repelling and killing efficacy, has proved the potentiation of compound preparation in the pertinent literature report.
3.4 this evidence 2 kinds of broad-spectrum de-worming medicines have obvious synergistic effect after compound, produced double dominant.

Claims (2)

1. a compound ivermectin injection is characterized in that every 100ml injection comprises: the propylene glycol of ivermectin 0.5~2g, albendazole-sulfoxide 2.5~10g, PEG400 5~15 ml, ethyl acetate 1~10ml, benzyl alcohol 0.5~2ml, α-thioglycerol 0.05~0.2ml, dimethyl sulfoxide 10~30ml and surplus.
2. the preparation method of the described a kind of compound ivermectin injection of claim 1, its step is as follows:
(1) takes by weighing ivermectin and join in the ethyl acetate, stir to clarify, get solution A;
(2) take by weighing albendazole-sulfoxide and join in the dimethyl sulfoxide, stop heating immediately after heating makes it to dissolve fully, be cooled to 40 ℃, stir to clarify, get solution B;
(3) merge solution A and solution B, add PEG400, α-thioglycerol and benzyl alcohol after stirring successively, stir, treat that solution clarification back adds propylene glycol, promptly gets compound ivermectin injection.
CN2011101119207A 2011-04-29 2011-04-29 Compound ivermectin injection and preparation method thereof Active CN102258529B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2011101119207A CN102258529B (en) 2011-04-29 2011-04-29 Compound ivermectin injection and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011101119207A CN102258529B (en) 2011-04-29 2011-04-29 Compound ivermectin injection and preparation method thereof

Publications (2)

Publication Number Publication Date
CN102258529A true CN102258529A (en) 2011-11-30
CN102258529B CN102258529B (en) 2013-02-13

Family

ID=45005495

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011101119207A Active CN102258529B (en) 2011-04-29 2011-04-29 Compound ivermectin injection and preparation method thereof

Country Status (1)

Country Link
CN (1) CN102258529B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081401A1 (en) * 2013-12-05 2015-06-11 Ouro Fino Saúde Animal Participações S.A. Method for preparing an anthelmintic composition, anthelmintic composition, veterinary treatment method and anthelmintic treatment method
CN105687294A (en) * 2016-03-10 2016-06-22 福建傲农生物科技集团股份有限公司 Novel parasite-expelling premix for pigs as well as preparation method and application of premix
WO2016157064A1 (en) * 2015-03-30 2016-10-06 Deva Holding Anonim Sirketi Stable ricobendazole formulations
CN109431983A (en) * 2018-11-30 2019-03-08 合肥中龙神力动物药业有限公司 A kind of compound ivermectin injection and preparation method thereof
CN114917221A (en) * 2022-05-27 2022-08-19 吉林吉力生物技术研究有限公司 Veterinary albendazole sulfoxide composition as well as preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1533770A (en) * 2003-03-26 2004-10-06 王玉万 Saspension injection containing benzimidazole kind vermifuge

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1533770A (en) * 2003-03-26 2004-10-06 王玉万 Saspension injection containing benzimidazole kind vermifuge

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081401A1 (en) * 2013-12-05 2015-06-11 Ouro Fino Saúde Animal Participações S.A. Method for preparing an anthelmintic composition, anthelmintic composition, veterinary treatment method and anthelmintic treatment method
US10052341B2 (en) 2013-12-05 2018-08-21 Ouro Fino Saude Animal Participacoes Sa Method for preparing an anthelmintic composition, anthelmintic composition, veterinary treatment method and anthelmintic treatment method
WO2016157064A1 (en) * 2015-03-30 2016-10-06 Deva Holding Anonim Sirketi Stable ricobendazole formulations
CN105687294A (en) * 2016-03-10 2016-06-22 福建傲农生物科技集团股份有限公司 Novel parasite-expelling premix for pigs as well as preparation method and application of premix
CN109431983A (en) * 2018-11-30 2019-03-08 合肥中龙神力动物药业有限公司 A kind of compound ivermectin injection and preparation method thereof
CN114917221A (en) * 2022-05-27 2022-08-19 吉林吉力生物技术研究有限公司 Veterinary albendazole sulfoxide composition as well as preparation method and application thereof

Also Published As

Publication number Publication date
CN102258529B (en) 2013-02-13

Similar Documents

Publication Publication Date Title
CN102258529B (en) Compound ivermectin injection and preparation method thereof
CN102697784B (en) Enrofloxacin injection for livestock and preparation method thereof
CN105994251A (en) Diluting and preserving solution for killing animal sperm viruses and bacteria
Carraschi et al. Effectiveness of therapeutic agents in disease treatment in Piaractus mesopotamicus
CN109512999A (en) The application of synergetic effect additive of the fatty alcohol of oxygen-containing hydrocarbon derivative as polymyxins
CN101972226B (en) Veterinary doxycycline hydrochloride injection and preparation method thereof
CN101417018B (en) Preparation method of animal injection capable of clearing away the heat-evil and expelling superficial evils, cooling blood and relieving dysentery
CN104800167A (en) Florfenicol soluble powder and preparation method thereof
CN106620668A (en) Compound tilmicosin solid dispersing agent and preparation method thereof
CN102000092B (en) New application of sulfadiazine sodium in preparing medicine for preventing or treating Bombyx mori septicemia
KR20030046491A (en) Treatment and prophylaxis of diseases and infections of pigs and poultry
CN101375856A (en) Compound ivermectin injection and preparation method
CN106554385B (en) Polypeptide compound and application thereof in livestock and poultry
CN108740356A (en) Purposes of the lauroyl arginine ethyl ester derivative as feed addictive
CN113908121A (en) Niclosamide injection and preparation and application thereof
CN103211818A (en) Pharmaceutical composition for treating or preventing bacterial and mycoplasma diseases of livestock and use thereof
RU2323718C2 (en) Medicine to treat young stock gastrointestinal diseases
CN112336706A (en) Veterinary amitraz solution synergist and preparation method thereof
US3888980A (en) Antimicrobial compounds of 2', 5'+0 substituted nitroanilides of substituted nitrosalicylic acid for quadruped animals
US6660262B2 (en) Broad spectrum antimicrobial compound and treatment
CN115317498B (en) Compound drop for treating canine and feline parasites and fungal skin diseases and preparation method thereof
CN105309441B (en) Composition pesticide containing nitrile pyrrole mite ester and its purposes in prevention and treatment harmful mite
CN112972437B (en) Long-acting external preparation containing iodonitrophenol and preparation method and application thereof
CN109364089A (en) It is a kind of with the composition and preparation method thereof for killing helminth effect
RU2639133C1 (en) Antiparastic means for pigs eimeriosis treatment and prevention

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CHANGSHA SPN ANIMAL PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: WUHAN HVSEN BIOTECHNOLOGY CO., LTD.

Effective date: 20121218

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 430042 WUHAN, HUBEI PROVINCE TO: 410329 CHANGSHA, HUNAN PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20121218

Address after: 410329 No. 11, shikonin Road, Changsha national biological industry base, Hunan

Applicant after: Changsha SPN Animal Pharmaceutical Co., Ltd.

Address before: 430042 Wuhan City, East and West Lake District, Taiwan Investment Zone Industrial Park, Bai Quan

Applicant before: Wuhan Hvsen Biotechnology Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant